Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Steroids Receptors" patented technology

Steroid hormone receptor. Steroid hormone receptors are found in the nucleus, cytosol, and also on the plasma membrane of target cells. They are generally intracellular receptors (typically cytoplasmic or nuclear) and initiate signal transduction for steroid hormones which lead to changes in gene expression over a time period of hours to days.

Method of expressing Heliothis ecdysone receptor fusion protein

The invention relates to an insect steroid receptor protein which is capable of acting as a gene switch which is responsive to a chemical inducer enabling external control of the gene.
Owner:SYNGENTA LTD

Compositions and methods for promoting nerve regeneration

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.
Owner:OREGON HEALTH & SCI UNIV

Compositions and methods for promoting nerve regeneration

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor-complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.
Owner:OREGON HEALTH & SCI UNIV

Methods for screening ligands that activate the translocation of a steroid receptor to the nucleus in mammalian cells

The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.
Owner:HAN HTUN

Polynucleotide encoding a novel human cytokine/steroid receptor

The present invention provides a human cytokine / steroid receptor protein (CYSTAR) and polynucleotides which identify and encode CYSTAR. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of CYSTAR, as well as diagnostic assays.
Owner:INCYTE PHARMA INC

Steroid receptor modulation of gene expression

InactiveUS20070077642A1Improve efficiencyHigh affinityFungiPeptidesEstrogen receptor bindingMammal
The present invention provides a novel steroid inducible expression system in a non-mammalian host cell (e.g., fungal) that is independent of metabolic and developmental regulation. The human estrogen receptor gene expressed in Aspergillus, under a constitutive promoter, was shown to be functional. A construct containing a promoter from Aspergillus, synthetic sequence containing the estrogen receptor biding sites (EREs) and a reporter gene was expressed in response to a hormone derivative inducer. In the absence of the inducer, the promoter is silent and depending on the type of construct and inducer concentration the expression level can be modulated from moderate to very strong.
Owner:GLYCOFI

Detection of steroid receptors on circulating carcinoma cells and treatment

The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent.
Owner:WELLSTAT BIOLOGICS CORP

Synergistic activation of regulatory elements by Rel proteins and a steroid receptor

Interaction of Rel proteins and steroid receptors is known to result in repression of target genes. Here we describe the discovery of a new mechanism in which Rel proteins and steroid receptors act synergistically to activate a regulatory element. This mechanism is shown to influence the expression of the brain-specific 5HT1A receptor wherein the estrogen receptor acts synergistically with the Nuclear Factor kappa B to enhance the activity of the promoter for the 5HT1A receptor gene. In addition, synergistic effects of Rel proteins with the mineralocorticoid receptor were observed, showing that synergism with Rel proteins may be expected for other steroid receptors as well. The synergism between Rel proteins and estrogen receptor or mineralocorticoid receptor provides a tool for the development of compounds that interact with the estrogen or mineralocorticoid receptor in such a way that only the synergistic effect is modulated whereas other effects are left intact. Such compounds would be invaluable for the development of medicaments for the treatment of diseases of the central nervous or cardiovascular system and other disorders in which Rel proteins play a role.
Owner:NV ORGANON

Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action

Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to the stereoisomerically unpurified form of the compound. These optically active compounds can be useful for obtaining reduction in moderate essential hypertension and it the treatment of congestive heart failure in humans with minimized undesirable side effects such as gynecomastia, tender breast enlargement and menstrual irregularities in women, and loss of libido in men.
Owner:SOMBERG JOHN C +1

Anti-cancer nuclear hormone receptor-targeting compounds

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
Owner:诺维逊生物股份有限公司

Chimeric protein comprising a green fluorescent ptotein fused to a transcription factor

The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.
Owner:HTUN HAN +1

Nucleic acids encoding estrogen receptor ligand binding domain variants

Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective “molecular gene switches” is disclosed. Methods of regulating gene function using these switches are provided.
Owner:NOVARTIS AG

Method and compositions for monitoring DNA binding molecules in living cells

The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.
Owner:HTUN HAN +1

Androgen receptor modulator compounds and methods

Compounds, pharmaceutical compositions, and methods for modulating processes mediated by steroid receptors. In particular, preparation and methods of use of non-steroidal compounds and compositions that are agonists, partial agonists, and antagonists for the androgen receptor (AR) are described. Further, described are the methods of making and use of critical intermediates including a stereoselective synthetic route to intermediates for the AR modulators.
Owner:LIGAND PHARMA INC

Cofactor that modulates steroid receptor activities

The invention provides a new glucocorticoid receptor coactivator named STAMP (Steroid receptor coactivator-1 and Transcription intermediary factor-2 Associated Modulatory Protein) that can modulate transcription of glucocorticoid-, progesterone-, mineralocorticoid- and androgen-responsive genes. The invention also provides antibodies that can bind STAMP and modulate its activity. In addition, the invention provides antisense, ribozyme and siRNA STAMP nucleic acids that can modulate the expression of STAMP. Also provided are compositions and methods for modulating glucocorticoid-responsive gene expression and for treating a variety of diseases and conditions.
Owner:UNITED STATES OF AMERICA

Pharmaceutical composition or group of compositions for inhibiting autocrine hcg production in adult human cells

A pharmaceutical composition for use as medicament that inhibits inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person / body-weight.
Owner:FLAMINA HLDG

Methods of dissociating nongenotropic from genotropic activity of steroid receptors

The present invention relates to fundamental discoveries for understanding the mechanism of non-gene targeting effects of steroids and its relation to gene targeting effects. It has been found that (i) non-gene targeting and gene targeting effects of steroids can be mediated through the same steroid receptors; (ii) both effects are ligand-induced; (iii) non-gene targeting effects occur is due to the ligand-inducing activity of the ligand-binding domain, which may be rapid and loose binding; (iv) gene targeting occurs due to the ligand of the DNA-binding domain of the steroid receptor induced activity, which is usually the result of a slower, stronger interaction; and (v) non-gene targeting of ligand interactions can be derived from gene targeting of ligand interactions separation so that selective reactions can be carried out. The present invention also discloses for the first time that certain steroids can induce non-gene targeting effects by binding to unrelated steroid receptors.
Owner:阿肯色大学评议会

Use of antagonists to the nuclear steroid receptor to inhibit coronaviruses

Compositions including at least one nuclear steroid family (NSF) receptor antagonist for the treatment or prevention of a coronavirus infection, such as SARS-CoV-2, and for the treatment of symptoms resulting from such infection. Also provided herein are methods of administering such compounds to a patient, either in a combination pharmaceutical formulation or in separate pharmaceutical formulations, to treat or prevent viral infections, including viral infections from coronaviruses such as SARS-CoV-2. Treatment decreases a viral load in a subject and / or may ameliorate symptoms associated with or produced by viral infection. Various administration modalities and mechanisms may be selected depending upon a condition of a patient and the patient's ability to be administered via a selected modality.
Owner:SPECTRAL ANALYTICS INC

Methods and Compositions for Modulating a Steroid Receptor

Methods, compositions, and uses are provided for modulating a steroid receptor or process mediated by a steroid receptor in a cell by administering a polypyridimine tract binding protein-associated splicing factor (PSF) polypeptide, a polynucleotide encoding the polypeptide, an isolated complex of a PSF polypeptide and a steroid receptor, and / or an agonist or antagonist thereof, in an effective amount to modulate the steroid receptor or process. Particular aspects of the invention relate to detection, monitoring, modulation, treatment and / or prevention of the onset of labor.
Owner:MOUNT SINAI HOSPITAL

Test kits and assays

The present invention provides in vitro test kits, assays and methods useful for screening a test sample for the presence of a ligand which is characterized by its ability to form a complex with a steroid hormone receptor and elicit a genomic response when in a cell. Advantageously, the activity-based assays which form the basis of the test kits and methods described herein, are particularly useful in detecting the presence of a ligand of unknown structure, for example, a designer drug used by equine, canine and human athletes in sports doping. Different assay prototypes are disclosed in whichactivation of the hormone receptor by a ligand binding interaction may be detected, for example, though activation of a reporter molecule. In certain examples, the present invention provides test kits, assays and methods involving aptame: fluorophore reporter constructs for detection of a ligand from (e.g.) a sample taken trackside from an athlete.
Owner:因斯图根有限公司

Small molecule regulators of steroid receptor coactivators and methods of use thereof

Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseasescan include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and / or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
Owner:BAYLOR COLLEGE OF MEDICINE

Potentiation of erythropoietin (EPO) action by membrane steroid receptor agonists

The present invention relates to the use of membrane steroid receptor agonists as potentiators of the action of erythropoietin (EPO). The present invention also relates to the combined use of membrane steroid receptor agonists and erythropoietin to control apoptosis, proliferation, differentiation, migration and regeneration of cells, in different organs and tissues. Compositions comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin are also provided, as are kits comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin.
Owner:BIONATURE E A LTD

Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells

A pharmaceutical composition for use as medicament that inhibits inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person / body-weight.
Owner:FLAMINA HLDG

Novel ligand assays

The present invention is concerned with the detection of ligands which bind to and activate steroid hormone receptors. Specifically, the present invention provides test kits and assay methods for the selective identification of steroid hormone receptor ligands from a test sample. Importantly, the test kits and assay methods described herein are cell-free, and do not require expensive-to-manufacture nuclear extracts for their performance. Instead, the test kits and assay methods described herein employ single polypeptide polymerases, such as T7 RNA polymerase, linked to a reporter construct. Activity of the enzyme is inhibited, rather than activated, by ligand-bound steroid hormone receptor complexes which only form in the presence of a target ligand. Accordingly, a measured change in a physical property of the reporter construct (e.g. fluorescence output) may be used to determine the presence of a target ligand in a sample under investigation.
Owner:OTAGO INNOVATION

Steroid modulators in the treatment of peripheral nerve sheath tumors

InactiveUS20050026878A1Prophylaxis andSuccessfully treat PNSTsBiocideOrganic active ingredientsMammalPR - Progesterone receptor
The invention features methods for treating and preventing a peripheral nerve sheath tumor in a mammal such as a human. The methods involve administering to the mammal a compound that modulates the biological activity of a gonatropic steroid receptor, such as the progesterone receptor in an amount sufficient to inhibit the growth of the peripheral nerve sheath tumor. The mammal may be administered with the compound alone or in combination with a second therapeutic regimen. Also disclosed are screening methods that make use of gonatropic steroid receptors for the identification of novel therapeutics for PNSTs.
Owner:MASSACHUSETTS INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products